Print page


Date of issue: January 2018
Version: 3

This is a UKTIS monograph for use by health care professionals. For case-specific advice please contact UKTIS on 0344 892 0909. To report an exposure please download and complete a pregnancy reporting form. Please encourage all women to complete an online reporting form.

A corresponding patient information leaflet on methylphenidate use in pregnancy is available at


Methylphenidate is a central nervous system stimulant used in the management of attention deficit hyperactivity disorder (ADHD). It is also used off-license in the treatment of narcolepsy.

The data regarding therapeutic use of methylphenidate do not suggest a significant increase in overall congenital or cardiac malformation rates, although a single study found an increased risk of conotruncal and major arch anomalies following exposure in utero. Increased risks of spontaneous abortion with methylphenidate use in early pregnancy and low Apgar score with use in later pregnancy have also been identified. Rates of intrauterine death, small for gestational age or preterm delivery have not been shown to be increased following pregnancy exposure, however the data are too limited to exclude an increase in risk. As with other CNS-acting drugs, neonatal withdrawal symptoms may be expected following the use of methylphenidate during pregnancy. There are no studies on the long-term effects of antenatal methylphenidate exposure on neurodevelopment.

Growth restriction and preterm delivery have been reported following abuse of methylphenidate in pregnancy. However, the data are too limited to confirm an association and concurrent risk factors for adverse pregnancy outcomes were present in most cases.

Exposure to methylphenidate at any stage of pregnancy would not usually be regarded as medical grounds for termination of pregnancy. However, other risk factors which independently increase the risk of adverse pregnancy outcome may be present in individual cases. Clinicians are reminded of the importance of consideration of such factors when performing case-specific risk assessments.
This document is regularly reviewed and updated. Only use full UKTIS monographs downloaded directly from to be sure you are using the most up-to-date version. The summaries of these monographs are openly available on

This is a summary of the full UKTIS monograph for health care professionals and should not be used in isolation. The full UKTIS monograph and access to any hyperlinked related documents is available to health care professionals at

If you have a patient with exposure to a drug or chemical and require assistance in making a patient-specific risk assessment, please telephone UKTIS on 0344 892 0909 to discuss the case with a teratology specialist.

If you would like to report a pregnancy to UKTIS please click here to download our pregnancy reporting form. Please encourage all women to complete an online reporting form.

Disclaimer: Every effort has been made to ensure that this monograph was accurate and up-to-date at the time of writing, however it cannot cover every eventuality and the information providers cannot be held responsible for any adverse outcomes of the measures recommended. The final decision regarding which treatment is used for an individual patient remains the clinical responsibility of the prescriber. This material may be freely reproduced for education and not for profit purposes within the UK National Health Service, however no linking to this website or reproduction by or for commercial organisations is permitted without the express written permission of this service. This document is regularly reviewed and updated. Only use UKTIS monographs downloaded directly from or to ensure you are using the most up-to-date version.